A. Giustina, G. Barkhoudarian, A. Beckers, A. Ben-Shlomo, N. Biermasz, B. Biller et al. Multidisciplinary management of acromegaly: a consensus. Rev. Endocr. Metab. Disord. 21, 667–678 (2020)

Article  PubMed  PubMed Central  Google Scholar 

G. Vila, J.O.L. Jørgensen, A. Luger, G.K. Stalla, Insulin resistance in patients with acromegaly. Front Endocrinol. (Lausanne) 10, 509 (2019)

Article  PubMed  Google Scholar 

D. Cuevas-Ramos, M. Fleseriu, Pasireotide: a novel treatment for patients with acromegaly. Drug Des. Dev. Ther. 10, 227–239 (2016)

CAS  Google Scholar 

M.R. Gadelha, L. Kasuki, D.S.T. Lim, M. Fleseriu, Systemic complications of acromegaly and the impact of the current treatment landscape: an update. Endocr. Rev. 40, 268–332 (2019)

Article  PubMed  Google Scholar 

I.M. Holdaway, R.C. Rajasoorya, G.D. Gamble, Factors influencing mortality in acromegaly. J. Clin. Endocrinol. Metab. 89, 667–674 (2004). p.

Article  CAS  PubMed  Google Scholar 

B. Zinman, C. Wanner, J.M. Lachin, D. Fitchett, E. Bluhmki, S. Hantel, M. Mattheus, T. Devins, O.E. Johansen, H.J. Woerle, U.C. Broedl, S.E. Inzucchi, EMPA-REG OUTCOME investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373, 2117–2128 (2015)

Article  CAS  PubMed  Google Scholar 

A. Giustina, A. Barkan, A. Beckers, N. Biermasz, B.M.K. Biller, C. Boguszewski et al. A consensus on the diagnosis and treatment of acromegaly comorbidities: an update. J. Clin. Endocrinol. Metab. 105, e937–e946 (2020).

M. Quarella, D. Walser, M. Brändle, J.Y. Fournier, S. Bilz, Rapid onset of diabetic ketoacidosis after SGLT2 inhibition in a patient with unrecognized acromegaly. J. Clin. Endocrinol. Metab. 102, 1451–1453 (2017)

Article  PubMed  Google Scholar 

N. Møller, J.O. Jørgensen, Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr. Rev. 30, 152–177 (2009)

Article  PubMed  Google Scholar 

S. Frara, F. Maffezzoni, G. Mazziotti, A. Giustina, Current and emerging aspects of diabetes mellitus in acromegaly. Trends Endocrinol. Metab. 27, 470–483 (2016)

Article  CAS  PubMed  Google Scholar 

F. Ferraù, A. Albani, A. Ciresi, C. Giordano, S. Cannavò, Diabetes secondary to acromegaly: physiopathology, clinical features and effects of treatment. Front Endocrinol. (Lausanne) 9, 358 (2018)

Article  PubMed  Google Scholar 

S. Kasayama, M. Otsuki, M. Takagi, H. Saito, S. Sumitani, H. Kouhara et al. Impaired beta-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients. Clin. Endocrinol. (Oxf.) 52, 549–555 (2000)

Article  CAS  PubMed  Google Scholar 

E. Karslioglu French, A.C. Donihi, M.T. Korytkowski, Diabetic ketoacidosis and hyperosmolar hyperglycemic syndrome: review of acute decompensated diabetes in adult patients. BMJ 365, 1114 (2019)

Article  Google Scholar 

E.A. Nyenwe, A.E. Kitabchi, The evolution of diabetic ketoacidosis: An update of its etiology, pathogenesis and management. Metabolism 65, 507–521 (2016)

Article  CAS  PubMed  Google Scholar 

A.E. Kitabchi, G.E. Umpierrez, J.M. Miles, J.N. Fisher, Hyperglycemic crises in adult patients with diabetes. Diabetes Care 32(7), 1335–1343 (2009)

Article  CAS  PubMed  PubMed Central  Google Scholar 

P. Ocampo, J.M. Duarte, R. Barcia, C. Arévalo, [Association between diabetic ketoacidosis and acromegaly]. Medicina (B Aires) 78, 131–133 (2018)

CAS  PubMed  Google Scholar 

N. Yoshida et al. Ketoacidosis as the initial clinical condition in nine patients with acromegaly: a review of 860 cases at a single institute. Eur. J. Endocrinol. 169, 127–132 (2013)

Article  CAS  PubMed  Google Scholar 

P. Nasa, S. Chaudhary, P.K. Shrivastava, A. Singh, Euglycemic diabetic ketoacidosis: a missed diagnosis. World J. Diabetes 12, 514–523 (2021)

Article  PubMed  PubMed Central  Google Scholar 

N. Fleming, P.S. Hamblin, D. Story, E.I. Ekinci, Evolving evidence of diabetic ketoacidosis in patients taking sodium-glucose co-transporter 2 inhibitors. J. Clin. Endocrinol. Metab. 105, 2475–2486 (2020)

E. Ferrannini, E. Muscelli, S. Frascerra, S. Baldi, A. Mari, T. Heise et al. Metabolic response to sodium-glucose co-transporter 2 inhibition in type 2 diabetic patients. J. Clin. Invest 124, 499–508 (2014)

Article  CAS  PubMed  PubMed Central  Google Scholar 

A. Zaina, Y. Grober, A. Abid, E. Arad, E. Golden, S. Badarny, Sodium glucose cotransporter 2 inhibitors treatment in acromegalic patients with diabetes-a case series and literature review. Endocrine 73, 65–70 (2021)

Article  CAS  PubMed  Google Scholar 

A.N. Sharma, M. Tan, E.A. Amsterdam, G.D. Singh, Acromegalic cardiomyopathy: epidemiology, diagnosis, and management. Clin. Cardiol. 41, 419–425 (2018)

Article  PubMed  PubMed Central  Google Scholar 

A. Colao, P. Marzullo, C. Di Somma, G. Lombardi, Growth hormone and the heart. Clin. Endocrinol. (Oxf.) 54, 137–154 (2001)

Article  CAS  PubMed  Google Scholar 

R. Pivonello, R.S. Auriemma, L.F. Grasso, C. Pivonello, C. Simeoli, R. Patalano et al. Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities. Pituitary 20, 46–62 (2017)

Article  PubMed  Google Scholar 

K. Wagdy, S. Nagy, EMPEROR-Preserved: SGLT2 inhibitors breakthrough in the management of heart failure with preserved ejection fraction. Glob. Cardiol. Sci. Pract. 2021, e202117 (2021)

PubMed  PubMed Central  Google Scholar 

M. Ragonese, A. Alibrandi, G. Di Bella, I. Salamone, S. Puglisi, O.R. Cotta et al. Cardiovascular events in acromegaly: distinct role of Agatston and Framingham score in the 5-year prediction. Endocrine 47, 206–212 (2014)

CAS  PubMed  Google Scholar 

C.M. Dos Santos Silva, G.A. Lima, I.C. Volschan, I. Gottlieb, L. Kasuki, L.V. Neto, M.R. Gadelha Low risk of coronary artery disease in patients with acromegaly. Endocrine 50, 749–755 (2015)

Article  PubMed  Google Scholar 

M. Fleseriu, Insight into cardiovascular risk factors in patients with acromegaly. Endocrine 47, 1–2 (2014)

Article  CAS  PubMed  Google Scholar 

P. Maffei, F. Dassie, A. Wennberg, M. Parolin, R. Vettor, The endothelium in acromegaly. Front Endocrinol. (Lausanne) 10, 437 (2019)

Article  PubMed  Google Scholar 

C.F. Messias de Lima, M.D. Dos Santos Reis, F.W. da Silva Ramos, S. Ayres-Martins, S. Smaniotto, Growth hormone modulates in vitro endothelial cell migration and formation of capillary-like structures. Cell Biol. Int 41, 577–584 (2017)

Article  CAS  PubMed  Google Scholar 

S. Tellatin, P. Maffei, E. Osto, F. Dassie, G. Famoso, R. Montisci et al. Coronary microvascular dysfunction may be related to IGF-1 in acromegalic patients and can be restored by therapy. Atherosclerosis 269, 100–105 (2018)

Article  CAS  PubMed  Google Scholar 

T.L.C. Wolters, M.G. Netea, A.R.M.M. Hermus, J.W.A. Smit, R.T. Netea-Maier, IGF1 potentiates the pro-inflammatory response in human peripheral blood mononuclear cells via MAPK. J. Mol. Endocrinol. 59, 129–139 (2017)

Article  CAS  PubMed  Google Scholar 

F. Bogazzi, L. Battolla, C. Spinelli, G. Rossi, S. Gavioli, V. Di Bello, F. Bogazzi et al. Risk factors for development of coronary heart disease in patients with acromegaly: a five-year prospective study. J. Clin. Endocrinol. Metab. 92, 4271–4277 (2007)

Article  CAS  PubMed  Google Scholar 

V.A. Ezzat, E.R. Duncan, S.B. Wheatcroft, M.T. Kearney, The role of IGF-I and its binding proteins in the development of type 2 diabetes and cardiovascular disease. Diabetes Obes. Metab. 10, 198–211 (2008)

Article  CAS  PubMed  Google Scholar 

T.L.C. Wolters, C.D.C.C. van der Heijden, N. van Leeuwen, B.T.P. Hijmans-Kersten, M.G. Netea, J.W. Smit, D.H.J. Thijssen, A. Hermus, N.P. Riksen, R. Netea-Maier, Persistent inflammation and endothelial dysfunction in patients with treated acromegaly. Endocr. Connect 8, 1553–1567 (2019)

Article  CAS  PubMed  PubMed Central  Google Scholar 

T.L.C. Wolters, M.G. Netea, N.P. Riksen, A.R.M.M. Hermus, R.T. Netea-Maier, Acromegaly, inflammation and cardiovascular disease: a review. Rev. Endocr. Metab. Disord. 21, 547–568 (2020)

Article  PubMed  PubMed Central  Google Scholar 

L. Boero, M. Manavela, L. Gómez Rosso, C. Insua, V. Berardi, M.C. Fornari, F. Brites, Alterations in biomarkers of cardiovascular disease (CVD) in active acromegaly. Clin. Endocrinol. (Oxf.) 70, 88–95 (2009)

Article  CAS  PubMed  Google Scholar 

F. Bonnet, A.J. Scheen, Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: the potential contribution to diabetes complications and cardiovascular disease. Diabetes Metab. 44, 457–464 (2018)

Article  CAS  PubMed  Google Scholar 

M. Oelze, S. Kröller-Schön, P. Welschof, T. Jansen, M. Hausding, Y. Mikhed et al. The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity. PLoS One 9, e112394 (2014)

Article  PubMed  PubMed Central